Vayarin
- Generic Name: lipirinen™ capsules
- Brand Name: Vayarin
Vayarin (Lipirinen™ Capsules) side effects drug center
Vayarin Side Effects Center
Vayarin (lipirinen) is a medical food used to manage certain lipid imbalances associated with ADHD. Common side effects of Vayarin include:
- abdominal pain,
- dry and itchy skin,
- tics,
- nausea,
- hyperactivity,
- tantrum,
- headache, and
- insomnia
The usual dose of Vayarin is 2 capsules daily or as directed by a physician. Vayarin may interact with anticholinergicand cholinergic medications. Tell your doctor all medications and supplements you use. Vayarin is not recommended for use during pregnancy or breastfeeding as it is unknown how it would affect a pregnancy, or a nursing infant.
Our Vayarin (lipirinen) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Vayarin Professional Information
SIDE EFFECTS
Adverse Events
The adverse events of Vayarin® were evaluated in a randomized, double blind, placebo-controlled study of 15 weeks followed by an open label extension of an additional 15 weeks [38].
Adverse events reported during the course of the double-blind phase (table 2): 12 participants from the Vayarin® group and 5 participants from the placebo group were classified by the study physicians as suffering from treatment related, or probably related, adverse events (13 and 5 adverse events, respectively). There were no significant differences between the study groups in either the incidence or number of adverse events recorded (P = 0.848 and P = 0.982, respectively).
Adverse events reported during the course of the open-label extension (table 2): 5 participants reported 7 adverse events that were classified by the study physicians as related or probably related to the study treatment.
Table 2
| Study design | Double-blind study (4 capsules/day) | Open-label extension (2 capsules/day) | |
| Treatment Group Adverse event* | Vayarin® (n=137) |
Placebo (n=63) |
Vayarin® (n=150) |
| Gastrointestinal discomfort | 6 | 4 | 4 |
| Atopic dermatitis | 1 | 0 | 0 |
| SGOT value | 1 | 0 | 0 |
| Headache | 0 | 1 | 1 |
| Insomnia | 0 | 0 | 1 |
| Tics | 1 | 0 | 0 |
| High triglycerides | 0 | 1 | 1 |
| Nausea | 1 | 0 | 0 |
| Hyperactivity | 1 | 0 | 0 |
| Tantrnm | 2 | 0 | 0 |
Table 2. Adverse events reported during the course of the double-blind and the open label phase.
*Judged by the study physicians as related or probably related to the study treatment
Drug Abuse
Vayarin® does not have any known drug abuse or withdrawal effects.
Read the entire FDA prescribing information for Vayarin (Lipirinen™ Capsules)
&Copy; Vayarin Patient Information is supplied by Cerner Multum, Inc. and Vayarin Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.